Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A Phase 3 Randomized Multicenter Trial to Compare Hepatic Progression-Free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drug-Eluting Bead Chemoembolization of Neuroendocrine Liver Metastases
The purpose of this study is 1) to determine if one or more of three techniques provide longer-lasting control of tumors in the liver, and 2) to see if outcomes for participants treated with the three techniques show that there are differences in quality of life, side effects, or safety.
To estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization.
Chemotherapy (NOS); Transarterial Chemoembolization (TACE)
Adriamycin (doxorubicin); Not Applicable (); doxorubicin ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.